Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Dotilavir Sodium vs Tivicay in Healthy Subjects
NCT05168176Phase 1Unknown
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Dec 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dolutegravir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoints: Peak Plasma Concentration at 31 days, Area under the plasma concentration versus time curve from time zero to the last measurable concentration at 31 days and 1 more. Status: unknown.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05168176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05168176.